Effect of Coenzyme Q10 as an adjunct therapy versus placebo on para-clinical signs after primary angioplasty of coronary artery in acute ST-elevation myocardial infarctio

Phase 3

Completed

• Conditions: ST elevation myocardial infarction.; ST elevation (STEMI) myocardial infarction of anterior wall; I21.0

• Registration Number: IRCT20120215009014N407
• Lead Sponsor: Hamedan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 March 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Age of 18 to 80 years;
Myocardial ischemia for at least 30 minutes;
Myocardial infarction disease in the last 12 hours;
Elevated ST segment on electrocardiogram;
Angioplasty for the first time;

Exclusion Criteria

Candidate for emergency coronary bypass surgery;
History of heart attack or heart failure or angioplasty;
Indication for thrombolytic therapy;
Cardiogenic shock;
Liver failure;
Autoimmune diseases or inflammation;
Taking antioxidant medicines in the past month;

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The serum level of troponin. Timepoint: Before angioplasty and 6, 12, 24, 48, and 72 hours after that. Method of measurement: By laboratory test.;The serum level of CK-MB. Timepoint: Before angioplasty and 6, 12, 24, 48, and 72 hours after that. Method of measurement: By laboratory test.;Thrombolysis in myocardial infarction (TIMI) flow grade. Timepoint: After angioplasty. Method of measurement: By laboratory test.;Myocardial blushing grade (MBG). Timepoint: After angioplasty. Method of measurement: By echocardiography.;ST-segment resolution. Timepoint: Immediately and 24 hours after angioplasty. Method of measurement: By echocardiography.;Left ventricular ejection fraction. Timepoint: 30 days after angioplasty. Method of measurement: By echocardiography.

Secondary Outcome Measures

Name	Time	Method
Adverse effects (heart failure, cardiogenic shock, re-infarction, and death). Timepoint: during the treatment period. Method of measurement: with taking history.